Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection

Pappanaicken R. Kumaresan, Pallavi R. Manuri, Nathaniel D. Albert, Sourindra Maiti, Harjeet Singh, Tiejuan Mi, Jason Roszik, Brian Rabinovich, Simon Olivares, Janani Krishnamurthy, Ling Zhang, Amer M. Najjar, M. Helen Huls, Dean A. Lee, Richard E. Champlin, Dimitrios P. Kontoyiannis, Laurence J N Cooper

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Clinical-grade T cells are genetically modified ex vivo to express chimeric antigen receptors (CARs) to redirect their specificity to target tumor-associated antigens in vivo. We now have developed this molecular strategy to render cytotoxic T cells specific for fungi. We adapted the pattern-recognition receptor Dectin-1 to activate T cells via chimeric CD28 and CD3-ζ (designated "D-CAR") upon binding with carbohydrate in the cell wall of Aspergillus germlings. T cells genetically modified with the Sleeping Beauty system to express D-CAR stably were propagated selectively on artificial activating and propagating cells using an approach similar to that approved by the Food and Drug Administration for manufacturing CD19-specific CAR+ T cells for clinical trials. The D-CAR+ T cells exhibited specificity for β-glucan which led to damage and inhibition of hyphal growth of Aspergillus in vitro and in vivo. Treatment of D-CAR + T cells with steroids did not compromise antifungal activity significantly. These data support the targeting of carbohydrate antigens by CAR+ T cells and provide a clinically appealing strategy to enhance immunity for opportunistic fungal infections using T-cell gene therapy.

Original languageEnglish (US)
Pages (from-to)10660-10665
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number29
DOIs
StatePublished - Jul 22 2014
Externally publishedYes

Fingerprint

Bioengineering
Mycoses
Opportunistic Infections
Carbohydrates
T-Lymphocytes
Antigen Receptors
Aspergillus
T-Cell Antigen Receptor
T-Cell Antigen Receptor Specificity
Pattern Recognition Receptors
Beauty
Glucans
Neoplasm Antigens
United States Food and Drug Administration
Cell- and Tissue-Based Therapy
Genetic Therapy
Cell Wall
Immunity
Fungi
Steroids

Keywords

  • Adoptive immunotherapy
  • Fungus
  • T-cell therapy
  • β-1,3-glucan

ASJC Scopus subject areas

  • General

Cite this

Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. / Kumaresan, Pappanaicken R.; Manuri, Pallavi R.; Albert, Nathaniel D.; Maiti, Sourindra; Singh, Harjeet; Mi, Tiejuan; Roszik, Jason; Rabinovich, Brian; Olivares, Simon; Krishnamurthy, Janani; Zhang, Ling; Najjar, Amer M.; Huls, M. Helen; Lee, Dean A.; Champlin, Richard E.; Kontoyiannis, Dimitrios P.; Cooper, Laurence J N.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 29, 22.07.2014, p. 10660-10665.

Research output: Contribution to journalArticle

Kumaresan, PR, Manuri, PR, Albert, ND, Maiti, S, Singh, H, Mi, T, Roszik, J, Rabinovich, B, Olivares, S, Krishnamurthy, J, Zhang, L, Najjar, AM, Huls, MH, Lee, DA, Champlin, RE, Kontoyiannis, DP & Cooper, LJN 2014, 'Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 29, pp. 10660-10665. https://doi.org/10.1073/pnas.1312789111
Kumaresan, Pappanaicken R. ; Manuri, Pallavi R. ; Albert, Nathaniel D. ; Maiti, Sourindra ; Singh, Harjeet ; Mi, Tiejuan ; Roszik, Jason ; Rabinovich, Brian ; Olivares, Simon ; Krishnamurthy, Janani ; Zhang, Ling ; Najjar, Amer M. ; Huls, M. Helen ; Lee, Dean A. ; Champlin, Richard E. ; Kontoyiannis, Dimitrios P. ; Cooper, Laurence J N. / Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 29. pp. 10660-10665.
@article{34415ab7ab444ff5addc0df9b34146e0,
title = "Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection",
abstract = "Clinical-grade T cells are genetically modified ex vivo to express chimeric antigen receptors (CARs) to redirect their specificity to target tumor-associated antigens in vivo. We now have developed this molecular strategy to render cytotoxic T cells specific for fungi. We adapted the pattern-recognition receptor Dectin-1 to activate T cells via chimeric CD28 and CD3-ζ (designated {"}D-CAR{"}) upon binding with carbohydrate in the cell wall of Aspergillus germlings. T cells genetically modified with the Sleeping Beauty system to express D-CAR stably were propagated selectively on artificial activating and propagating cells using an approach similar to that approved by the Food and Drug Administration for manufacturing CD19-specific CAR+ T cells for clinical trials. The D-CAR+ T cells exhibited specificity for β-glucan which led to damage and inhibition of hyphal growth of Aspergillus in vitro and in vivo. Treatment of D-CAR + T cells with steroids did not compromise antifungal activity significantly. These data support the targeting of carbohydrate antigens by CAR+ T cells and provide a clinically appealing strategy to enhance immunity for opportunistic fungal infections using T-cell gene therapy.",
keywords = "Adoptive immunotherapy, Fungus, T-cell therapy, β-1,3-glucan",
author = "Kumaresan, {Pappanaicken R.} and Manuri, {Pallavi R.} and Albert, {Nathaniel D.} and Sourindra Maiti and Harjeet Singh and Tiejuan Mi and Jason Roszik and Brian Rabinovich and Simon Olivares and Janani Krishnamurthy and Ling Zhang and Najjar, {Amer M.} and Huls, {M. Helen} and Lee, {Dean A.} and Champlin, {Richard E.} and Kontoyiannis, {Dimitrios P.} and Cooper, {Laurence J N}",
year = "2014",
month = "7",
day = "22",
doi = "10.1073/pnas.1312789111",
language = "English (US)",
volume = "111",
pages = "10660--10665",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "29",

}

TY - JOUR

T1 - Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection

AU - Kumaresan, Pappanaicken R.

AU - Manuri, Pallavi R.

AU - Albert, Nathaniel D.

AU - Maiti, Sourindra

AU - Singh, Harjeet

AU - Mi, Tiejuan

AU - Roszik, Jason

AU - Rabinovich, Brian

AU - Olivares, Simon

AU - Krishnamurthy, Janani

AU - Zhang, Ling

AU - Najjar, Amer M.

AU - Huls, M. Helen

AU - Lee, Dean A.

AU - Champlin, Richard E.

AU - Kontoyiannis, Dimitrios P.

AU - Cooper, Laurence J N

PY - 2014/7/22

Y1 - 2014/7/22

N2 - Clinical-grade T cells are genetically modified ex vivo to express chimeric antigen receptors (CARs) to redirect their specificity to target tumor-associated antigens in vivo. We now have developed this molecular strategy to render cytotoxic T cells specific for fungi. We adapted the pattern-recognition receptor Dectin-1 to activate T cells via chimeric CD28 and CD3-ζ (designated "D-CAR") upon binding with carbohydrate in the cell wall of Aspergillus germlings. T cells genetically modified with the Sleeping Beauty system to express D-CAR stably were propagated selectively on artificial activating and propagating cells using an approach similar to that approved by the Food and Drug Administration for manufacturing CD19-specific CAR+ T cells for clinical trials. The D-CAR+ T cells exhibited specificity for β-glucan which led to damage and inhibition of hyphal growth of Aspergillus in vitro and in vivo. Treatment of D-CAR + T cells with steroids did not compromise antifungal activity significantly. These data support the targeting of carbohydrate antigens by CAR+ T cells and provide a clinically appealing strategy to enhance immunity for opportunistic fungal infections using T-cell gene therapy.

AB - Clinical-grade T cells are genetically modified ex vivo to express chimeric antigen receptors (CARs) to redirect their specificity to target tumor-associated antigens in vivo. We now have developed this molecular strategy to render cytotoxic T cells specific for fungi. We adapted the pattern-recognition receptor Dectin-1 to activate T cells via chimeric CD28 and CD3-ζ (designated "D-CAR") upon binding with carbohydrate in the cell wall of Aspergillus germlings. T cells genetically modified with the Sleeping Beauty system to express D-CAR stably were propagated selectively on artificial activating and propagating cells using an approach similar to that approved by the Food and Drug Administration for manufacturing CD19-specific CAR+ T cells for clinical trials. The D-CAR+ T cells exhibited specificity for β-glucan which led to damage and inhibition of hyphal growth of Aspergillus in vitro and in vivo. Treatment of D-CAR + T cells with steroids did not compromise antifungal activity significantly. These data support the targeting of carbohydrate antigens by CAR+ T cells and provide a clinically appealing strategy to enhance immunity for opportunistic fungal infections using T-cell gene therapy.

KW - Adoptive immunotherapy

KW - Fungus

KW - T-cell therapy

KW - β-1,3-glucan

UR - http://www.scopus.com/inward/record.url?scp=84904632405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904632405&partnerID=8YFLogxK

U2 - 10.1073/pnas.1312789111

DO - 10.1073/pnas.1312789111

M3 - Article

VL - 111

SP - 10660

EP - 10665

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 29

ER -